Properties
- Form
- tableti
- Dosage mg
- 12.5
- Pack
- 28
What is it?
International Nonproprietary Name - Carvedilolum Pharmacological group: Antianginal agents Dosage form and content: Oral tablets. The tablet contains 6.25 mg, or 12.5 mg, or 25 mg of the active substance carvedilol, as well as excipients: lactose monohydrate, sucrose, anhydrous colloidal silicon dioxide, povidone, crospovidone, and magnesium stearate. Tablets 6.25 mg contain Quinoline Yellow, while 12.5 mg tablets contain Sunset Yellow. Pharmacotherapeutic group: Alpha-, beta-adrenoblocker Indications for use • Essential hypertension – for monotherapy and in combination with diuretics • Chronic stable angina • Chronic heart failure (NYHA Class II and III) * in combination with diuretics, digoxin, or angiotensin-converting enzyme inhibitors * - NYHA (New York Heart Association) – II: Patients in this stage have no symptoms at rest, moderate physical exertion is accompanied by fatigue, palpitations, and shortness of breath (shortness of breath) * - NYHA – III: No symptoms at rest. Minor physical exertion causes the above symptoms. Method of administration and dosage Tablets are taken orally. Swallow whole with a small amount of liquid. For patients with heart failure, it is recommended to take the drug during meals to reduce the risk of orthostatic syndrome. Treatment should be discontinued by gradually reducing the dose. For essential hypertension: Recommended starting dose 12.5 mg once daily for 2 days (one 12.5 mg tablet in the morning or two 6.25 mg tablets twice daily – one in the morning, one in the evening). Recommended maintenance dose 25 mg (one 25 mg tablet in the morning or two 12.5 mg tablets twice daily – one in the morning, one in the evening). If the result is unsatisfactory, but not earlier than the 14th day of treatment, the dose can be increased to the maximum – 50 mg per day (one 25 mg tablet twice daily – morning and evening). The maximum single dose is 25 mg, and the daily dose should not exceed 50 mg. Recommended starting dose 3.125 mg twice daily for 14 days (1/2 tablet of 6.25 mg in the morning and evening). If the patient tolerates the treatment well and it is necessary, the dose can be increased to 6.25 mg twice daily (one 6.25 mg tablet in the morning and one in the evening). The dose can be further increased to 12.5 mg twice daily (one 12.5 mg tablet in the morning and evening), then to 25 mg twice daily (one 25 mg tablet in the morning and evening). Patients are prescribed the maximum tolerated dose. The maximum recommended dose is 25 mg twice daily (one 25 mg tablet in the morning and one in the evening) for patients weighing up to 85 kg and 50 mg twice daily (two 25 mg tablets in the morning and two in the evening) for patients weighing over 85 kg. To avoid orthostatic hypotension in patients with heart failure, it is recommended to take the drug during meals. Side effects At recommended doses, the drug is usually well tolerated, but in individual cases, side effects may occur: Central nervous system: headache, drowsiness, fatigue, rarely – depressed mood, sleep disturbances, paresthesias. Cardiovascular system: orthostatic hypotension, bradycardia, marked decrease in blood pressure, angina attacks, rarely – peripheral circulatory disorders (cold extremities), intermittent claudication or Raynaud's syndrome, peripheral edema, atrioventricular block, progression of heart failure. Respiratory system: shortness of breath, bronchospasm, rare – nasal congestion. Gastrointestinal tract: dry mouth, vomiting, nausea, diarrhea, abdominal pain, rarely – constipation, nausea, increased activity of serum transaminases. Skin: allergic exanthema, urticaria, itching, exacerbation of psoriatic rash, very rarely – anaphylactoid reactions.
